The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1336
L-Methylfolate (Deplin) for Depression and Schizophrenia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

L-methylfolate (Deplin — Pamlab) is a “medical food” marketed for adjunctive use in depression or schizophrenia in patients with suboptimal folate levels.1 It is available only by prescription.

MEDICAL FOODS — The Orphan Drug Act Amendments of 1988 define a medical food as “a food which is formulated to be consumed or administered enterally under the supervision of a physician, and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.” Medical foods are exempt from labeling requirements for health claims and nutrient content. They are regulated, but not registered, reviewed or approved, by the FDA.

RATIONALE — The primary suggested mechanism of action claimed for L-methylfolate in depression is that it aids ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: L-Methylfolate (Deplin) for Depression and Schizophrenia
Article code: 1336d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian